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MethodsIntroduction
Objective
▪ Among 8 participants who may experience
sub- or supra-therapeutic effects of SSRIs
based on their pharmacogenomic results, 2
participants, especially, are at increased risk
of serious adverse effect of citalopram-
induced prolonged QT interval.
▪ Pharmacogenomics can improve patients’
health and reduce or prevent these kinds of
adverse drug effects by predicting the drug-
gene interactions.4
Virginia Commonwealth University 
▪ Depressive and anxiety disorders are
among the most common illnesses
experienced by older adults (age > 60).1
▪ The selective serotonin reuptake
inhibitors (SSRIs) are preferred class of
antidepressants for these disorders due to
their high efficacy and safety profiles
among older adults.1
▪ However, SSRIs are mainly metabolized
by cytochrome P450 enzymes,
specifically CYP2D6 and CYP2C19,
which are known to be polymorphic in
populations of African descent.2 This can
lead to variable dose-response outcomes,
especially among older African
American population.
▪ Pharmacogenomic data of CYP enzymes
can be utilized to predict possible SSRI
drug-gene interactions, as part of
delivering precision medicine.
Key: PM = poor metabolizer (presence of two null alleles). IM = intermediate metabolizer (presence of either two reduced function
alleles or one null allele and one reduced function allele). NM = normal metabolizer (presence of one normal allele plus another
normal or reduced function allele). RM = rapid metabolizer (presence of one normal allele and one increased function allele).
UM = ultrarapid metabolizer (presence of two increased function alleles).
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To analyze the frequency of 
CYP2D6 and CYP2C19 
polymorphisms in African American 
older adults who are taking SSRIs 
and to identify potential 
inappropriate use of SSRIs in these 
older adults using the Clinical 
Pharmacogenetics Implementation 
Consortium (CPIC) guideline for 
SSRIs.  
▪ Overall, only 2 participants had wild type for both CYP2D6 and CYP2C19. The rest of the participants
had at least one variant allele that results in decreased or increased activity level of the CYP2D6 and
CYP2C19 enzymes.
▪ After matching the participants’ enzyme activity levels of CYP2D6 and CYP2C19 and the major
metabolic pathway of their agent of SSRIs, about ⅔ of the participants are at risk for drug-gene
interaction (Fig. 2).
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▪ DNA samples of 64 participants (age >
60), who were enrolled into
Translational Approaches to
Personalized Health (TAPH) study,
were collected via Ora-gene saliva kits
and analyzed using the PGx Express
Chip on the QuantStudio 12K Flex
system.3
▪ Among 64 participants, we focused on
the genotypes of only 12 participants,
who were taking SSRIs.
▪ After data collection, phenotypes were
assigned to the genotypes of the 12
participants based on the CPIC
Guideline for CYP2D6 and CYP2C19
genotypes of SSRIs (Fig. 1).2
▪ TAPH is still enrolling participants.
However, we were still able to observe high
prevalence of CYP2D6 and CYP2C19
variant alleles and identify potential drug-
gene interactions in this study. After reaching
our enrollment goal of 250 African
Americans older adults (age > 60) into the
TAPH study, we will perform statistical
analyses of their genotypes of CYP2D6 and
CYP2C19 polymorphisms.
▪ Participants’ SSRI dosing, measures of
depressive and anxiety disorders, and self-
reported drug side-effects will be collected to
compare with the CPIC guidelines and
further identify inappropriate use of SSRIs in
these older adults.
Figure 1. CYP2D6 and CYP2C19 phenotypes of participants taking SSRIs
Figure 2: Participants at increased risk of
subtherapeutic or supratherapeutic response
of SSRIs based on their pharmacogenomic
results. *The adverse effect most concerned in
the CPIC guideline was citalopram-induced
prolonged QT interval.
